The Department of Health and Social Care (UK) is announcing the launch of a £10 million (approximately €11,3 million) research competition to fund innovations to tackle antimicrobial resistance in humans.
Multimillion grants have been awarded to four UK universities to conduct interdisciplinary research into the biological, social, cultural and economic drivers behind the development of antimicrobial resistance (AMR).
Evotec signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives.
GSK published the results of its Survey of Antibiotic Resistance in Russia. The collected data revealed high sensitivity of the main bacteria causing respiratory infections to amoxicillin/clavulanate and fluoroquinolones.
A British nanotech company has created a potentially life changing technology that aims to overcome the global crisis of antibiotic resistance. Researchers from AGA Nanotech have developed a unique alternative to antibiotics.
A team of researchers led by Brown University infectious disease experts and engineers has identified a new class of antibiotics that could one day help combat the alarming emergence of drug-resistant “superbugs.”
The Dutch regulator has raised concerns about a shortage of narrow-spectrum antibiotics. A lack of targeted therapies is forcing doctors to use broad-spectrum antibiotics that increase the risk of antimicrobial resistance.
Novo Holdings announced the launch of an impact fund with a total budget of $165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.
The research project DRIVE-AB has determined that a market entry reward of $1 billion per antibiotic globally could significantly increase the number of new antibiotics coming to the market in the next 30 years